Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01799603
Recruitment Status : Completed
First Posted : February 27, 2013
Last Update Posted : April 29, 2013
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

Brief Summary:
The purpose of this study is to investigate the effect of food on the pharmacokinetics (explores what the body does to the drug) and safety of TMC435 in Japanese healthy adult male participants.

Condition or disease Intervention/treatment Phase
Healthy Drug: TMC435 Phase 1

Detailed Description:
This is an open-label (all people know the identity of the intervention), single-center, 2-way crossover (method used to switch participants from one treatment arm to another in a clinical trial) and randomized (the study drug is assigned by chance) study to assess the effect of food on the pharmacokinetics of TMC435 after a single dose in Japanese healthy adult male participants. The study duration will be of 44 days per participant, which is divided into 3 parts: Screening (from Day -28 to Day -2); Treatment (consists of 2 treatment periods of 5 days each [that is, Day -1 to 4, in-patient period], wherein all participants will receive TMC435 in the respective period, and the period will be separated by washout period of 9 days); and Follow-up (on Day 7 of Period 2). Participants will keep upright position from the time of study drug administration until 4 hours after study drug administration. Participants will not be allowed to ingest meal until 4 hours post-dose. Participants will have standardized lunch and dinner at 4 hours and 10 hours post-dose, respectively. Drinking water will not be allowed from 1 hour before the administration up to 1 hour after administration except for the water served with the study drug and meal. Pharmacokinetics will be assessed in blood samples which will be collected up to 72 hours after administration of study drug. Participants' safety will be monitored throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-dose, Open-label, Randomized, Two-way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of TMC435 in Japanese Healthy Adult Male Subjects
Study Start Date : May 2012
Actual Primary Completion Date : July 2012
Actual Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Simeprevir

Arm Intervention/treatment
Experimental: TMC435 in fasted then fed condition
Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
Drug: TMC435
TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Other Name: G008

Experimental: TMC435 in fed then fasted condition
Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
Drug: TMC435
TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
Other Name: G008




Primary Outcome Measures :
  1. Maximum Plasma Concentration (C[max]) [ Time Frame: -3 hours (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Day 1 ]
    The C(max) is the maximum plasma concentration.

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[infinity]) [ Time Frame: -3 hours (pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Day 1 ]
    The AUC (infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC (last) and C (last)/lambda (z), wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time; and C (last) is the last observed quantifiable concentration; and lambda (z) is elimination rate constant.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be a Japanese man aged 20 to 40 years, inclusive at the day of informed consent being signed
  • Must agree to use an adequate contraception method (for example, double-barrier method) as deemed appropriate by the Investigators during the study and for 3 months after receiving the last dose of study drug
  • Body mass index (BMI) between 18.5 and 25.0 kilogram per square meter (kg/m^2) and body weight not less than 50 kilogram
  • Blood pressure (after the participant is supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic
  • Non-smoker or participant who has quitted any tobacco or nicotine containing products more than one year prior to screening

Exclusion Criteria:

  • History of or current clinically significant medical illness including (but not limited to), cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the Investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Use of any prescription or non-prescription medication (including vitamins and supplements) within 14 days before the administration on Day 1 of treatment Period 1
  • History of drug or alcohol abuse within the past 5 years and positive test for drugs of abuse, such as cannabinoids, opiates, cocaine, amphetamines, benzodiazepines or barbiturates and serum alcohol test
  • Known allergy to the study drug or any of the excipients of the formulation
  • Participated in another clinical study and received another study drugs administration or used an experimental medical device within 120 days or within a period less than 10 times the drug's half life, whichever is longer, before Day 1 of the first treatment period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01799603


Locations
Layout table for location information
Japan
Toshima, Japan
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Layout table for investigator information
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Layout table for additonal information
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01799603    
Other Study ID Numbers: CR100854
TMC435HPC1007
First Posted: February 27, 2013    Key Record Dates
Last Update Posted: April 29, 2013
Last Verified: April 2013
Keywords provided by Janssen Research & Development, LLC:
Healthy
TMC435
G008
Additional relevant MeSH terms:
Layout table for MeSH terms
Simeprevir
Antiviral Agents
Anti-Infective Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action